| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Inogen, Inc$6.54
+0.01 (+0.15%)
F 15Pipeline Score MedTech · Commercial
Market Cap
173.28 M
EPS
-0.92
P/E Ratio
-
Value Trade
2.63 M
SEC Financials
Q1 2026Dilution Risk
Revenue
85.11 M
R&D Expenses
5.10 M
Operating CF
-6.68 M
Total Assets
285.93 M
Total Liabilities
103.02 M
Equity
182.91 M
D/E Ratio
12,345
-4.62 %
Week
-8.44 %
1 Month
10.34 %
3 Month
-2.88 %
6 Month
-90.21 %
5 Year
-60 %
All Time
Cash Data
Cash Position
110.17 M
Monthly Burn
2.23 M
Runway
47.5 mo
Burn Trend
SEC Filing
May 8, 2026
Overview
Volume
155.45 K
52 Week Range
5.34 - 9.13
% held by Insiders
3.57 %
% held by Institutions
70.74 %
Enterprise Value
78.74 M
Total Shares
27.07 M
Short %
4.36 %
Float Shares
23.55 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Inogen, Inc
1Total events
0Upcoming
0Tier-1 (high impact)
2026 – 2026Coverage
Event history 1
Drug Pipeline Intelligence
F15
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 11%
Micro Cap (rank 812 of 911)
Percentile RankInogen, Inc has significant pipeline risk (15/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INGN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INGNInogen Announces the Appointment of Andy Reding as Chief Operating Officer
Inogen has announced the appointment of Andy Reding as the new Chief Operating Officer. This strategic move is expected to leverage Reding's extensive experience in the industry to improve operational efficiencies and drive growth within the company. The leadership change reflects Inogen's commitment to strengthening its management team.
Read more →INGNInogen Announces First Quarter 2026 Financial Results Reported first quarter year-over-year revenue growth of 3.4% Company reiterates full-year 2026 guidance
Inogen, Inc. reported a 3.4% increase in revenue for Q1 2026 compared to the same quarter in the previous year, exceeding internal forecasts. The company reiterated its full-year guidance, projecting continued growth driven by international demand for portable oxygen concentrators and new product launches. However, despite revenue growth, Inogen recorded an increased net loss and negative adjusted EBITDA, indicating ongoing challenges in the domestic market. The firm has initiated several strategic initiatives, including a share repurchase program and new product developments, to bolster future growth prospects.
Read more →INGNInogen Announces the Appointment of Vafa Jamali to Board of Directors
Inogen, Inc. has appointed Vafa Jamali as an independent director to its Board, effective at the upcoming 2026 Annual Meeting. Jamali, a seasoned medical device executive, is expected to contribute valuable insights and strategic leadership, benefiting Inogen’s transformation into a diversified respiratory care platform. His history of driving growth and profitability at established companies encourages optimism about Inogen's future performance. The announcement also includes a cooperation agreement with Kent Lake Partners to support the company's strategic initiatives.
Read more →INGNInogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Inogen, Inc. has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This announcement reflects the company's compliance with regulatory requirements for equity awards. Further details on the specific grants or their implications were not provided in the article.
Read more →INGNInogen Announces Leadership Appointments Designed to Accelerate Next Phase of Growth Jason Richardson Named Chief Financial Officer, Succeeding Michael Bourque Dominic Hulton Named Chief Marketing Officer Corey Moritz Ap
Inogen, Inc. has announced several key leadership appointments designed to support its next phase of growth. Jason Richardson has been appointed as Chief Financial Officer, succeeding Michael Bourque, who will continue in an advisory role. Dominic Hulton is named Chief Marketing Officer, aimed at enhancing the company's global brand and expanding customer engagement. Corey Moritz also joins as Vice President of U.S. Business to Business Sales, bringing extensive experience in commercial transformation and revenue growth. The management changes come as the company reaffirms its financial outlook for the first quarter and full year of 2026.
Read more →INGNInogen Announces $30 Million Share Repurchase Program
Inogen, Inc. has announced a $30 million share repurchase program authorized by its Board of Directors. This initiative is intended to enhance shareholder value and reflects the company's confidence in its long-term growth strategy. The program will be financed through cash flow and existing reserves and is set to expire by December 31, 2027, or once the maximum amount is utilized.
Read more →INGNInogen Announces Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Outlook Delivered full year revenue growth of approximately 4% Significantly improved profitability with 2025 net loss of $
Inogen, Inc. announced its financial results for the fourth quarter and full year of 2025, reporting a revenue growth of approximately 4% and an improved profitability with a GAAP net loss of $22.7 million. The company achieved a positive adjusted EBITDA for the first time since 2021 and introduced new products aimed at enhancing its market position. Looking ahead to 2026, Inogen anticipates continued growth with expected revenues ranging from $366 million to $373 million, although it warns of potential declines in U.S. rentals revenue due to changing reimbursement dynamics.
Read more →INGN▼ -11.7%on this news
Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025 Inogen to Announce Fourth Quarter and Full Year 2025 Financial Results on
Inogen, Inc. (Nasdaq: INGN) announced its preliminary revenue results for the fourth quarter and full year 2025, estimating fourth quarter revenue of around $82 million, reflecting a 2% year-over-year increase, and a total annual revenue of approximately $349 million, a 4% growth. The company is maintaining a focus on financial discipline and anticipates achieving positive adjusted EBITDA for the full year. Despite some delays in large customer orders pushing into 2026, Inogen reports ongoing progress in its business turnaround and product innovation.
Read more →INGN▼ -8.3%on this news
Inogen Announces Third Quarter 2025 Financial Results Delivered seventh consecutive quarter of mid-single-digit revenue growth Reiterating full-year revenue guidance
Inogen, Inc. reported its financial results for Q3 2025, achieving $92.4 million in revenue, a 4.0% year-over-year increase. This marks the seventh consecutive quarter of revenue growth. The company also posted a positive adjusted EBITDA of $2.3 million and reiterated its full-year revenue guidance of $354 million to $357 million. However, it reported a GAAP net loss of $5.3 million and a decline in gross margin compared to the previous year, highlighting some ongoing challenges.
Read more →INGN▼ -6.8%on this news· ran to +20% by day 3
Inogen Announces Second Quarter 2025 Financial Results Delivered strong top-line results; raising full year 2025 revenue expectations
Inogen, Inc. reported its financial results for the second quarter of 2025, highlighting a revenue of $92.3 million, marking a 4% year-over-year growth. The company announced the launch of its new oxygen concentrator, Voxi 5, and positive adjusted EBITDA for the second consecutive quarter. However, it also faced a GAAP net loss of $4.2 million and a decline in gross margin compared to last year. Due to strong performance in the first half of the year, Inogen has raised its full-year revenue guidance.
Read more →INGNInogen Announces First Quarter 2025 Financial Results
Inogen, Inc. has announced its financial results for the first quarter of 2025, showcasing a revenue increase to $82.3 million, up 5.5% from the previous year. The company's gross margin improved slightly, while operating expenses decreased significantly by 13.1%. However, despite these improvements, Inogen reported a net loss of $6.2 million. Moving forward, the company projects revenues for the full year to range between $352 million and $355 million, reflecting continued growth expectations.
Read more →INGNInogen Announces Fourth Quarter and Full Year 2024 Financial Results • Results Reflect Strong Fourth Quarter 2024 Revenue Growth of 5.5%; Full-Year Revenue Growth of 6.4% • Company Provides 2025 Growth Outl
Inogen, Inc. has reported its financial results for the fourth quarter and full year of 2024, highlighting revenue growth of 5.5% in Q4 and 6.4% for the year. The improvements are attributed to increased demand in both domestic and international business-to-business sales, although direct-to-consumer sales declined. The company anticipates continued growth in 2025, aided by a strategic collaboration with Yuwell, which enhances its global market potential.
Read more →INGNInogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West
Inogen, Inc. has announced the appointment of Mira Kirti Sahney to its Board of Directors, effective January 31, 2025, following the retirement of Tom West. Sahney brings significant management and operational experience from her previous roles in the medical device field. Inogen's Chairperson, Elizabeth Mora, expressed enthusiasm about Sahney's addition, highlighting her capabilities to advance the company’s position in respiratory care. The announcement emphasizes a period of transformation and growth for Inogen.
Read more →INGNInogen Expands Product Portfolio, Global Reach and Innovation Pipeline Through Strategic Collaboration with Yuwell
Inogen, Inc. has announced a strategic collaboration with Yuwell aimed at expanding its product portfolio and enhancing its innovation pipeline. This partnership will facilitate the distribution of Inogen's respiratory products in the United States and other regions, while also aiding the company's entry into the Chinese market. Additionally, Yuwell will invest approximately $27.2 million into Inogen, increasing its equity stake. The collaboration is expected to accelerate Inogen's growth and satisfy the needs of respiratory patients globally.
Read more →INGN▲ +8.2%on this news
Inogen Announces Preliminary Fourth Quarter and Full Year 2024 Revenue
Inogen, Inc. has announced its preliminary revenue results for the fourth quarter and full year ending December 31, 2024. The company estimates Q4 revenue between $79 million and $80 million, reflecting a year-over-year growth of 4% to 5%. For the full year, Inogen expects revenue between $334.5 million and $335.5 million, surpassing previous guidance. The positive performance is attributed to strong business-to-business growth and new product launches aimed at enhancing patient care in respiratory therapy.
Read more →INGN▲ +6.2%on this news
Inogen Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance Device GOLETA, Calif., –
Inogen, Inc. has announced that it received FDA 510(k) clearance for its SIMEOX 200 Airway Clearance Device, enabling it to market this innovative product for patients with chronic respiratory diseases. This next-generation device enhances bronchial drainage through high frequency oscillatory vibrations and is aimed at conditions such as COPD and Cystic Fibrosis. Inogen plans to initiate a limited launch of the SIMEOX 200 in targeted sites in 2025, leveraging its established network of healthcare providers for broad distribution. The approval represents a significant step in expanding patient access to respiratory therapies.
Read more →INGNInogen Announces Third Quarter 2024 Financial Results GOLETA, Calif., –
Inogen, Inc. announced its financial results for the third quarter of 2024, reporting a revenue increase of 5.8% compared to the same quarter last year, amounting to $88.8 million. Significant improvements were seen in gross margin and a substantial decrease in operating expenses due to the absence of a one-time goodwill impairment charge. The adjusted EBITDA showed a positive turnaround, reflecting effective cost management and strategic initiatives. However, the company still reported a GAAP net loss, indicating ongoing challenges in the direct-to-consumer market segment.
Read more →INGNInogen Announces Second Quarter 2024 Financial Results GOLETA, Calif., –
Inogen, Inc. reported its Q2 2024 financial results, with total revenue rising 6.1% to $88.8 million compared to the previous year. The company noted improvements in gross margin, which jumped to 48.1%, and achieved positive adjusted EBITDA of $1.3 million. However, direct-to-consumer sales and rental revenue declined, leading to a GAAP net loss of $5.6 million, although this was an improvement from $9.8 million in Q2 2023. Looking ahead, Inogen forecasts full-year 2024 revenue in the range of $325 million to $330 million, reflecting growth expectations.
Read more →INGN▲ +5.3%on this news
Inogen Strengthens Leadership Team with Appointment of New General Counsel and Executive Vice President, Business Development
Inogen, Inc. has appointed Kevin P. Smith as its new General Counsel and Executive Vice President of Business Development, effective July 22, 2024. Mr. Smith brings nearly 30 years of experience from leadership roles at various companies, including Sirtex Medical and Novartis Pharmaceuticals. The appointment is expected to fortify Inogen's leadership, particularly in areas of legal and business development, contributing to the company's integrity and compliance goals in the medical technology field.
Read more →INGNInogen Announces First Quarter 2024 Financial Results GOLETA, Calif., –
Inogen, Inc. reported its financial results for the first quarter of 2024, highlighting an 8.1% increase in total revenue to $78 million compared to the same quarter in 2023. The company's gross margin improved to 44.1%, and operating expenses decreased by 3.8%. Despite a GAAP net loss of $14.6 million, Inogen anticipates revenue growth in the second quarter, expecting to generate between $81 million and $84 million. The leadership expressed optimism about the future while acknowledging challenges related to direct-to-consumer sales and competition.
Read more →INGNInogen Announces Fourth Quarter and Full-Year 2023 Financial Results Fourth quarter 2023 revenue of $75.9 million; full-year 2023 revenue of $315.7 million Goleta, CA –
Inogen, Inc. reported its financial results for the fourth quarter and full-year of 2023, revealing a total revenue of $75.9 million in Q4 and $315.7 million for the year. The company experienced a decline in sales due to decreases in business-to-business and direct-to-consumer sales but reported improved gross margins. Despite the net loss of $26.6 million in Q4, the management remains optimistic about future growth and innovation, targeting revenue of $73 to $74 million for the first quarter of 2024.
Read more →INGNInogen Names Michael Bourque As New Chief Financial Officer Goleta, CA –
Inogen, Inc. has appointed Michael Bourque as the new Chief Financial Officer, effective March 4, 2024. Bourque, who previously held CFO positions at Chase Corporation and other firms, is expected to help Inogen enhance its financial strategy and operations. He succeeds Mike Sergesketter, who will remain with the company in an advisory role. The leadership change is positioned as a key move to bolster Inogen's capabilities in delivering innovative respiratory products to patients.
Read more →INGNInogen Announces Leadership Change with the Appointment of Kevin Smith as President and CEO Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Drivi
Inogen, Inc. has appointed Kevin Smith as its new President and CEO, effective immediately, succeeding Nabil Shabshab. Smith comes with over 20 years of experience in the medical device sector and is expected to drive growth and operational efficiencies within the company. The board believes his leadership will support Inogen's next phase and capitalize on its market potential, particularly in portable oxygen therapy solutions. However, the leadership transition has prompted Inogen to cancel its appearances at two upcoming healthcare conferences.
Read more →INGNInogen Announces Third Quarter 2023 Financial Results
Inogen, Inc. reported a decrease in total revenue of 20.3% for the third quarter of 2023, totaling $84.0 million. The company has made strides with the acquisition of Physio-Assist SAS, which expands its presence in the airway clearance market. However, this quarter also saw a significant GAAP net loss due to substantial impairment charges and increased operating expenses. Inogen continues to focus on returning to revenue growth and efficiency in operations moving forward.
Read more →INGNInogen Completes Acquisition of Physio-Assist Acquisition Expands Inogen's Global Respiratory Care Presence by Addressing the Sizeable, Growing and Underserved Airway Clearance Market Opportunity
Inogen has successfully acquired Physio-Assist, thereby enhancing its respiratory care offerings with the Simeox device aimed at airway clearance. This acquisition provides Inogen with access to a sizable market and aligns with its strategy to become a leader in global respiratory solutions. While the integration of Simeox is expected to have minimal immediate financial impact, it is anticipated to enhance gross margin and introduce recurring revenue streams starting from 2027. The device is already established in international markets, allowing Inogen to leverage its infrastructure for marketing while pursuing regulatory approvals in the U.S.
Read more →INGNINOGEN ANNOUNCES CFO TRANSITION PLAN – Names Mike Sergesketter as Interim Chief Financial Officer– –Reaffirms 2023 Financial Guidance– Goleta, CA –
Inogen, Inc. has appointed Mike Sergesketter as Interim Chief Financial Officer following the resignation of Kristin Caltrider. Sergesketter, who previously held this role, brings over forty years of finance expertise. The company has reaffirmed its financial expectations for 2023, projecting annual revenue between $315 million and $320 million and a planned Adjusted EBITDA loss. Inogen is engaging an executive search firm to identify a permanent CFO.
Read more →INGNInogen Announces Second Quarter 2023 Financial Results
Inogen, Inc. has reported its financial results for the second quarter of 2023, showing a significant revenue decline of 19.1% to $83.6 million. The company reported a GAAP net loss of $9.8 million, and a negative Adjusted EBITDA of $3.2 million. Despite this, Inogen is pursuing a strategic acquisition of Physio-Assist, which aims to enhance its portfolio and market presence. Additionally, the company introduced a new portable oxygen concentrator, Inogen Rove 6, to strengthen its competitive edge.
Read more →INGNInogen Expands Its Respiratory Product Portfolio with Acquisition of Physio-Assist Acquisition Enables Evolution to a Global Respiratory Care Company by Adding a Sizable, Growing and Underserved Airway Clearance Market O
Inogen, Inc. has announced its acquisition of Physio-Assist SAS, which will enhance its respiratory product portfolio by adding the Simeox airway clearance device, currently marketed in Europe and other regions. This acquisition is designed to align with Inogen's goals of portfolio diversification and expansion into the large bronchiectasis market. The deal, valued at approximately $32 million with performance-based milestones, is expected to generate positive financial impacts starting in 2027. However, the transaction is still subject to regulatory approvals and other customary conditions.
Read more →INGNInogen Announces First Quarter 2023 Financial Results Total Revenue of $72.2 Million In Line with Company Expectations Rental Revenue Year-over-Year Growth of 25%
Inogen, Inc. reported its first-quarter 2023 financial results, revealing total revenue of $72.2 million, which is in line with company expectations despite a year-over-year decrease of 10.2%. The company achieved a 25.4% increase in rental revenue, owing to a rise in rental patients and reimbursement rates. However, the GAAP net loss widened to $20.3 million, and adjusted EBITDA was negative at $11.8 million. Looking ahead, Inogen remains optimistic about returning to profitability with anticipated positive adjusted EBITDA by Q4 2023.
Read more →INGNInogen Announces Appointment of Tom West to Board of Directors and Retirement of Board Member Kristen Miranda
Inogen, Inc. announced the appointment of Tom West to its Board of Directors, effective April 1, 2023, while Kristen Miranda will retire from the Board on March 31, 2023. Tom West brings a wealth of experience from his leadership roles in medical technology, which is expected to enhance Inogen’s growth strategy. The company aims to strengthen its position in the respiratory care sector under the leadership of its new board member and the current CEO, Nabil Shabshab. Inogen continues to innovate in the development of portable oxygen concentrators for patients with chronic respiratory conditions.
Read more →INGNInogen Announces Fourth Quarter and Full Year 2022 Financial Results Fourth Quarter Year-over-Year Revenue Growth of 15.3% Full Year 2022 Year-over-Year Revenue Growth of 5.4%
Inogen, Inc. (INGN) has reported its financial results for the fourth quarter and full year of 2022, highlighting a year-over-year revenue growth of 15.3% in Q4 and 5.4% for the full year. Despite these gains, the company also faced substantial losses, with a GAAP net loss of $56.6 million in Q4 and an overall GAAP net loss of $83.8 million for 2022 compared to the previous year. The total operating expenses rose sharply, indicating challenges in managing costs while pursuing growth strategies. Inogen remains committed to its innovation pipeline and rental strategy to drive future growth.
Read more →INGNInogen Announces Preliminary Fourth Quarter and Full Year 2022 Revenue Within Company Expectations Inogen to Present at J.P. Morgan Healthcare Conference This Week Inogen to Announce Fourth Quarter and Full Year 2022 Fin
Inogen, Inc. has announced preliminary unaudited revenue results for the fourth quarter and full year ended December 31, 2022, indicating growth within expected ranges. The company estimates fourth quarter revenues to be between $87.5 million and $88.5 million, marking a year-over-year increase of 14.5% to 15.8%. Despite facing macroeconomic pressures and operational challenges, Inogen's revenue results align closely with prior guidance. The company will present its financial results more comprehensively at the J.P. Morgan Healthcare Conference and is set to announce finalized outcomes on February 23, 2023.
Read more →INGN▼ -7.9%on this news
Inogen Announces Third Quarter 2022 Financial Results Double Digit Year-over-Year Revenue Growth of 13.2% Constant Currency Year-over-Year Revenue Growth of 14.5%
Inogen Announces Third Quarter 2022 Financial Results Double Digit Year-over-Year Revenue Growth of 13.2% Constant Currency Year-over-Year Revenue Growth of 14.5% GOLETA, Calif., November 02, 2022 Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative re
Read more →INGNInogen Announces Second Quarter 2022 Financial Results Robust Sequential Revenue Growth Driven by Fulfilled Demand
Inogen Announces Second Quarter 2022 Financial Results Robust Sequential Revenue Growth Driven by Fulfilled Demand GOLETA, Calif., August 04, 2022 Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting,
Read more →INGN▼ -5.5%on this news
Inogen Announces First Quarter 2022 Financial Results - Q1 2022 Total Revenue of $80.4 million - Goleta, California
Inogen Announces First Quarter 2022 Financial Results - Q1 2022 Total Revenue of $80.4 million - Goleta, California, May 5, 2022 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported
Read more →INGN▼ -5.3%on this news
Inogen Announces Board of Director Changes Glenn Boehnlein, Kevin King and Mary Kay Ladone Appointed as Independent Directors Goleta, California
Inogen Announces Board of Director Changes Glenn Boehnlein, Kevin King and Mary Kay Ladone Appointed as Independent Directors Goleta, California, March 23, 2022 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the h
Read more →INGNInogen Names Kristin Caltrider as Chief Financial Officer Goleta, California
Inogen Names Kristin Caltrider as Chief Financial Officer Goleta, California, March 4, 2022 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Kristin Caltrider
Read more →INGN▲ +6.5%on this news· ran to +25% by day 3
Inogen Announces Fourth Quarter and Full Year 2021 Financial Results - Q4 2021 Total Revenue increased 3.3% year-over-year to $76.4 million - Goleta, California
Inogen Announces Fourth Quarter and Full Year 2021 Financial Results - Q4 2021 Total Revenue increased 3.3% year-over-year to $76.4 million - Goleta, California, February 24, 2022 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory produc
Read more →INGN▼ -9%on this news
Inogen Announces Preliminary, Unaudited Full Year and Fourth Quarter 2021 Revenue Results - Q4 2021 Total Preliminary Revenue of $75.9 to $76.9 million - - Provides Supply Chain and EU Operations Up
Inogen Announces Preliminary, Unaudited Full Year and Fourth Quarter 2021 Revenue Results - Q4 2021 Total Preliminary Revenue of $75.9 to $76.9 million - - Provides Supply Chain and EU Operations Update - Goleta, California, January 10, 2022 - Inogen, Inc. (NASDAQ: INGN), a m
Read more →INGNINOGEN APPOINTS ELIZABETH MORA AS BOARD CHAIRPERSON - Ray Huggenberger Retires from Board - Goleta, CA
INOGEN APPOINTS ELIZABETH MORA AS BOARD CHAIRPERSON - Ray Huggenberger Retires from Board - Goleta, CA - December 30, 2021 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that
Read more →INGNINOGEN ANNOUNCES CFO TRANSITION PLAN - Names Mike Sergesketter as Interim Chief Financial Officer- Goleta, CA
INOGEN ANNOUNCES CFO TRANSITION PLAN - Names Mike Sergesketter as Interim Chief Financial Officer- Goleta, CA - December 13, 2021 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announce
Read more →INGNInogen Announces Third Quarter 2021 Financial Results - Q3 2021 Total Revenue increased 25.3% from the same period in 2020 to $93.1 million - Goleta, California
Inogen Announces Third Quarter 2021 Financial Results - Q3 2021 Total Revenue increased 25.3% from the same period in 2020 to $93.1 million - Goleta, California, November 4, 2021 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory product
Read more →INGNInogen (INGN) Shareholder Litigation Alert: Should Inogen Management be Held Accountable for Investors Losses? Contact Johnson Fistel, LLP Regarding Pending Derivative Case
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, the court-appointed Lead Counsel in a derivative action brought for the benefit of Inogen, Inc. (NASDAQ: INGN) and its shareholders, announces today that a securities fraud class action pending before U.S. Distri
Read more →INGN▲ +5.3%on this news· ran to -23% by day 1
Inogen Announces Second Quarter 2021 Financial Results - Q2 2021 Record Total Revenue of $101.6 million, up 41.7% from the same period in 2020 - Goleta, California
Inogen Announces Second Quarter 2021 Financial Results - Q2 2021 Record Total Revenue of $101.6 million, up 41.7% from the same period in 2020 - Goleta, California, August 4, 2021 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory produc
Read more →INGNInogen Strengthens Board of Directors with Addition of Elizabeth Mora Goleta, California
Inogen Strengthens Board of Directors with Addition of Elizabeth Mora Goleta, California, May 24, 2021 -Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that Elizabeth (Beth) Mora
Read more →INGNInogen Announces First Quarter 2021 Financial Results - Q1 2021 Total Revenue of $86.9 million - - Q1 2021 Rental Revenue of $9.9 million, up 84.2% from the same period in 2020 - Goleta, California
Inogen Announces First Quarter 2021 Financial Results - Q1 2021 Total Revenue of $86.9 million - - Q1 2021 Rental Revenue of $9.9 million, up 84.2% from the same period in 2020 - Goleta, California, May 4, 2021 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offeri
Read more →INGNInogen Announces Appointment of Chief Commercial Officer, Transition of Certain Officers, and Preliminary, Unaudited First Quarter 2021 Revenue Range - George Parr to join as Executive Vice Presiden
Inogen Announces Appointment of Chief Commercial Officer, Transition of Certain Officers, and Preliminary, Unaudited First Quarter 2021 Revenue Range Goleta, California, April 7, 2021 -Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory pro
Read more →INGNInogen Announces Fourth Quarter 2020 Financial Results - Q4 2020 Total Revenue of $74.0 million - - Q4 2020 Rental Revenue of $9.4 million, up 71.7% from the same period in 2019 - Goleta, California
Inogen Announces Fourth Quarter 2020 Financial Results - Q4 2020 Total Revenue of $74.0 million - - Q4 2020 Rental Revenue of $9.4 million, up 71.7% from the same period in 2019 - Goleta, California, February 24, 2021 - Inogen, Inc. (NASDAQ: INGN), a medical technology company
Read more →INGNAbout Inogen We are a medical technology company offering innovative respiratory products for use in the homecare setting. We primarily develop, manufacture and market innovative portable oxygen concentrators used to del
Inogen Strengthens Board of Directors with Addition of Kristen Miranda Goleta, California, February 16, 2021 -Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that Kristen Miranda
Read more →INGNNotice Regarding Forward-Looking Statements These slides and the accompanying oral presentation (the "Presentation") include forward-looking statements within the meaning of the Private Securities Litigation Reform Act o
Company Overview January 2021 Exhibit 99.1 Notice Regarding Forward-Looking Statements These slides and the accompanying oral presentation (the "Presentation") include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which ar
Read more →INGNInogen Announces Third Quarter 2020 Financial Results - Q3 2020 Total Revenue of $74.3 million - Goleta, California
Inogen Announces Third Quarter 2020 Financial Results - Q3 2020 Total Revenue of $74.3 million - Goleta, California, November 4, 2020 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today repo
Read more →INGNInogen Announces Second Quarter 2020 Financial Results - Q2 2020 Total Revenue of $71.7 million - Goleta, California
Inogen Announces Second Quarter 2020 Financial Results - Q2 2020 Total Revenue of $71.7 million - Goleta, California, August 4, 2020 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today repor
Read more →INGNInogen CEO Announces Intent to Retire Before End of 2021; Inogen Commences Search for Successor Goleta, California
Inogen CEO Announces Intent to Retire Before End of 2021; Inogen Commences Search for Successor Goleta, California, June 9, 2020 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced
Read more →INGNInogen Announces First Quarter 2020 Financial Results - Q1 2020 Total Revenue of $88.5 million - - Withdraws 2020 Guidance - Goleta, California
Inogen Announces First Quarter 2020 Financial Results - Q1 2020 Total Revenue of $88.5 million - - Withdraws 2020 Guidance - Goleta, California, May 5, 2020 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the home
Read more →INGNInogen Announces Fourth Quarter and Full Year 2019 Financial Results and Updates 2020 Guidance Goleta, California
Inogen Announces Fourth Quarter and Full Year 2019 Financial Results and Updates 2020 Guidance Goleta, California, February 25, 2020 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today report
Read more →INGNInogen Announces Preliminary, Unaudited Full Year and Fourth Quarter 2019 Revenue Results - Q4 2019 Total Preliminary Revenue of $78.4 to $79.4 million - - Updates 2020 Guidance - Goleta, California
Inogen Announces Preliminary, Unaudited Full Year and Fourth Quarter 2019 Revenue Results - Q4 2019 Total Preliminary Revenue of $78.4 to $79.4 million - - Updates 2020 Guidance - Goleta, California, January 13, 2020 - Inogen, Inc. (NASDAQ: INGN), a medical technology company
Read more →INGNInogen Announces Third Quarter 2019 Financial Results - Q3 2019 Total Revenue of $91.8 million - - Confirms 2019 Guidance and Provides Initial 2020 Guidance - Goleta, California
Inogen Announces Third Quarter 2019 Financial Results - Q3 2019 Total Revenue of $91.8 million - - Confirms 2019 Guidance and Provides Initial 2020 Guidance - Goleta, California, November 5, 2019 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative r
Read more →INGNNotice regarding forward-looking statements These slides and the accompanying oral presentation (the "Presentation") include forward-looking statements within the meaning of the Private Securities Litigation Reform Act o
Company Overview September 2019 Exhibit 99.1 Notice regarding forward-looking statements These slides and the accompanying oral presentation (the "Presentation") include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which
Read more →INGNInogen Announces Second Quarter 2019 Financial Results and Updates 2019 Guidance - Q2 2019 Record Total Revenue of $101.1 million - - Inogen has Entered into a Definitive Agreement to Acquire New Ae
Inogen Announces Second Quarter 2019 Financial Results and Updates 2019 Guidance - Q2 2019 Record Total Revenue of $101.1 million - - Inogen has Entered into a Definitive Agreement to Acquire New Aera - Goleta, California, August 7, 2019 - Inogen, Inc. (NASDAQ: INGN), a medic
Read more →INGNInogen Announces First Quarter 2019 Financial Results and Updates 2019 Guidance - Q1 2019 Sales Revenue up 14.1% Over the Same Period in 2018 - Goleta, California
Inogen Announces First Quarter 2019 Financial Results and Updates 2019 Guidance - Q1 2019 Sales Revenue up 14.1% Over the Same Period in 2018 - Goleta, California, May 7, 2019 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products f
Read more →INGNINOGEN SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Inogen, Inc. - INGN
NEW ORLEANS, May 03, 2019 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 6, 2019 to file lead plaintiff applications in a securities class action lawsuit against Inogen, Inc. (NasdaqGS: INGN), if they purchased
Read more →INGNINOGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Inogen, Inc. - INGN
NEW ORLEANS, April 19, 2019 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 6, 2019 to file lead plaintiff applications in a securities class action lawsuit a
Read more →INGNINOGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Inogen, Inc. – INGN
NEW ORLEANS, March 22, 2019 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 6, 2019 to file lead plaintiff applications in a securities class action lawsuit a
Read more →INGNINOGEN, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Inogen, Inc.
NEW YORK, March 12, 2019 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against Inogen, Inc. (“Inogen” or the “Company”) (Nasdaq: INGN) in the United States District Court for the Central District of Californi
Read more →INGNInogen Announces Fourth Quarter and Full Year 2018 Financial Results and Updates 2019 Guidance - Q4 2018 Sales Revenue up 38.4% Over the Same Period in 2017 - - Record Revenue for Full Year 2018 - G
Inogen Announces Fourth Quarter and Full Year 2018 Financial Results and Updates 2019 Guidance - Q4 2018 Sales Revenue up 38.4% Over the Same Period in 2017 - - Record Revenue for Full Year 2018 - Goleta, California, February 26, 2019 - Inogen, Inc. (NASDAQ: INGN), a medical t
Read more →INGNInogen Announces Third Quarter 2018 Financial Results - Q3 2018 Sales Revenue up 42.1% Over the Same Period in 2017 - - Provides Updated 2018 Guidance and Initial 2019 Guidance - Goleta, California
Inogen Announces Third Quarter 2018 Financial Results - Q3 2018 Sales Revenue up 42.1% Over the Same Period in 2017 - - Provides Updated 2018 Guidance and Initial 2019 Guidance - Goleta, California, November 6, 2018 - Inogen, Inc. (NASDAQ: INGN), a medical technology company o
Read more →INGNInogen Announces Management Changes Goleta, California
Inogen Announces Management Changes Goleta, California, August 28, 2018 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that after nearly 15 years of dedicated support to Inogen
Read more →INGNInogen Announces Record Second Quarter 2018 Financial Results and Increases 2018 Guidance - Q2 2018 Sales Revenue up 58.5% Over the Same Period in 2017 - Goleta, California
Inogen Announces Record Second Quarter 2018 Financial Results and Increases 2018 Guidance - Q2 2018 Sales Revenue up 58.5% Over the Same Period in 2017 - Goleta, California, August 7, 2018 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respirato
Read more →INGNInogen Announces Record First Quarter 2018 Financial Results and Increases 2018 Guidance - Q1 2018 Sales Revenue up 60.1% Over the Same Period in 2017 - Goleta, California
Inogen Announces Record First Quarter 2018 Financial Results and Increases 2018 Guidance - Q1 2018 Sales Revenue up 60.1% Over the Same Period in 2017 - Goleta, California, April 30, 2018 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respirator
Read more →INGNInogen Announces Fourth Quarter and Full Year 2017 Financial Results and Updates 2018 Guidance - Q4 2017 Sales Revenue up 37.0% Over the Same Period in 2016 - - Record Revenue for Full Year 2017 - -
Inogen Announces Fourth Quarter and Full Year 2017 Financial Results and Updates 2018 Guidance - Q4 2017 Sales Revenue up 37.0% Over the Same Period in 2016 - - Record Revenue for Full Year 2017 - - Raises 2018 Guidance - Goleta, California, February 27, 2018 - Inogen, Inc. (
Read more →INGNInogen Announces Record Third Quarter 2017 Financial Results - Q3 2017 Sales Revenue up 33.8% Over the Same Period in 2016 - - Q3 2017 Net Income up 39.9% Over the Same Period in 2016 - - Raises 201
Inogen Announces Record Third Quarter 2017 Financial Results - Q3 2017 Sales Revenue up 33.8% Over the Same Period in 2016 - - Q3 2017 Net Income up 39.9% Over the Same Period in 2016 - - Raises 2017 Guidance and Provides 2018 Guidance - Goleta, California, November 7, 2017 -
Read more →INGNInogen Announces Record Second Quarter 2017 Financial Results - Q2 2017 Sales Revenue up 27.3% Over the Same Period in 2016 - - Q2 2017 Net Income up 11.3% Over the Same Period in 2016 - - Increasin
Inogen Announces Record Second Quarter 2017 Financial Results - Q2 2017 Sales Revenue up 27.3% Over the Same Period in 2016 - - Q2 2017 Net Income up 11.3% Over the Same Period in 2016 - - Increasing 2017 Guidance - Goleta, California, August 3, 2017 - Inogen, Inc. (NASDAQ: I
Read more →INGNInogen Announces First Quarter 2017 Financial Results - Q1 2017 Sales Revenue up 40.1% Over the Same Period in 2016 - - Q1 2017 Net Income up 135.3% Over the Same Period in 2016 - - Updating 2017 Gu
Inogen Announces First Quarter 2017 Financial Results - Q1 2017 Sales Revenue up 40.1% Over the Same Period in 2016 - - Q1 2017 Net Income up 135.3% Over the Same Period in 2016 - - Updating 2017 Guidance - Goleta, California, May 9, 2017 - Inogen, Inc. (NASDAQ: INGN), a medi
Read more →INGNInogen Announces Fourth Quarter and Full Year 2016 Financial Results and Updates 2017 Guidance - Q4 2016 Sales Revenue up 47.2% Over the Same Period in 2015 - - Q4 2016 Net Income up 36.3% Over the
Inogen Announces Fourth Quarter and Full Year 2016 Financial Results and Updates 2017 Guidance - Q4 2016 Sales Revenue up 47.2% Over the Same Period in 2015 - - Q4 2016 Net Income up 36.3% Over the Same Period in 2015 - - Q4 2016 Adjusted Net Income up 85.0% Over the Same Peri
Read more →INGNInogen Provides Impact from 21 st Century Cures Act - Impact of 21 st Century Cures Act expected to be positive for 2016 results- Goleta, California
FOR IMMEDIATE RELEASEExhibit 99.1 Inogen Provides Impact from 21st Century Cures Act - Impact of 21st Century Cures Act expected to be positive for 2016 results- Goleta, California, January 9, 2017 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative
Read more →INGNInogen Announces Management Transitions and Expanded Board of Directors - Scott Wilkinson to Succeed Raymond Huggenberger as CEO Effective
Inogen Announces Management Transitions and Expanded Board of Directors - Scott Wilkinson to Succeed Raymond Huggenberger as CEO Effective March 1, 2017 and Join the Board of Directors Effective January 1, 2017 - - Scott Beardsley to Join the Board of Directors Effective Januar
Read more →INGNInogen Announces Third Quarter 2016 Financial Results - Q3 2016 Sales Revenue up 61.3% Over the Same Period in 2015 - - Q3 2016 Adjusted Net Income up 61.4% Over the Same Period in 2015 - - Raises 2
Inogen Announces Third Quarter 2016 Financial Results - Q3 2016 Sales Revenue up 61.3% Over the Same Period in 2015 - - Q3 2016 Adjusted Net Income up 61.4% Over the Same Period in 2015 - - Raises 2016 Revenue Guidance and Provides 2017 Guidance- Goleta, California, November
Read more →INGNInogen Announces Second Quarter 2016 Financial Results - Record Revenue and Net Income Quarter - - Q2 2016 Sales Revenue up 40.7% Over the Same Period in 2015 - - Q2 2016 Net Income up 48.7% Over th
Inogen Announces Second Quarter 2016 Financial Results - Record Revenue and Net Income Quarter - - Q2 2016 Sales Revenue up 40.7% Over the Same Period in 2015 - - Q2 2016 Net Income up 48.7% Over the Same Period in 2015 - - Increases 2016 Guidance - Goleta, California, Augus
Read more →INGNInogen Announces First Quarter 2016 Financial Results - Q1 2016 Sales Revenue up 42.4% Over the Same Period in 2015 - - Q1 2016 Net Income up 50.4% Over the Same Period in 2015 - - Reiterates 2016 G
Inogen Announces First Quarter 2016 Financial Results - Q1 2016 Sales Revenue up 42.4% Over the Same Period in 2015 - - Q1 2016 Net Income up 50.4% Over the Same Period in 2015 - - Reiterates 2016 Guidance - Goleta, California, May 9, 2016 - Inogen, Inc. (NASDAQ: INGN), a med
Read more →INGNCORRECTION...by Inogen, Inc. GOLETA, Calif.--(BUSINESS WIRE)-- In the news release, Inogen Announces First Quarter 2016 Financial Results, issued on
CORRECTION...by Inogen, Inc. GOLETA, Calif.--(BUSINESS WIRE)-- In the news release, Inogen Announces First Quarter 2016 Financial Results, issued on May 9, 2016 by Inogen, Inc., we are advised by the Company that in the table in the section entitled "Reconciliation of U.S. GAAP
Read more →INGNInogen Announces Fourth Quarter and Full Year 2015 Financial Results and Updates 2016 Guidance - Record Revenue and Profitability for Full Year 2015 - - Fourth Quarter 2015 Revenue and Profitability
Inogen Announces Fourth Quarter and Full Year 2015 Financial Results and Updates 2016 Guidance - Record Revenue and Profitability for Full Year 2015 - - Fourth Quarter 2015 Revenue and Profitability Exceed Expectation - - Raises Guidance for 2016 - Goleta, California, March 1
Read more →INGNCompany Overview January 2016 Notice regarding forward-looking statements These slides and the accompanying oral presentation (the "Presentation") include forward-looking statements within the meaning of the Private Secu
Notice regarding forward-looking statements These slides and the accompanying oral presentation (the "Presentation") include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates a
Read more →INGNInogen Announces Participation in Upcoming Investor Conferences
GOLETA, Calif., Dec. 23, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that the Company’s management will be participating in two upcoming investor confer
Read more →INGNInogen Releases Enhanced Inogen One G3 Oxygen Concentrator
GOLETA, Calif., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has released to market an enhanced Inogen One G3 portable oxygen concentrato
Read more →INGNInogen Provides Additional Full Year 2016 Guidance - Reaffirms 2015 Guidance
Inogen Provides Additional Full Year 2016 Guidance - Reaffirms 2015 Guidance - GOLETA, Calif., November 30, 2015 -- Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that it antici
Read more →INGNInogen Provides Additional Full Year 2016 Guidance
GOLETA, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that it anticipates adjusted EBITDA for the full year 2016 to be in the range of $3
Read more →INGNInogen, Inc. (Nasdaq: INGN) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Alison Bauerlein, Byron Mye
Read more →INGNInogen to Recognize National COPD Awareness Month at The Nasdaq Stock Market Closing Bell Ceremony
GOLETA, Calif., Nov. 18, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it will ring The Nasdaq Stock Market closing bell in New York City on November 19,
Read more →INGNInogen Announces Third Quarter 2015 Financial Results
- Q3 2015 Revenue Growth of 38.7% Over the Same Period in 2014 - - Raises 2015 Revenue Guidance and Provides 2016 Revenue Guidance - GOLETA, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory produc
Read more →INGNInogen Announces Third Quarter 2015 Financial Results - Q3 2015 Revenue Growth of 38.7% Over the Same Period in 2014 - - Raises 2015 Revenue Guidance and Provides 2016 Revenue Guidance- Goleta, Cali
Inogen Announces Third Quarter 2015 Financial Results - Q3 2015 Revenue Growth of 38.7% Over the Same Period in 2014 - - Raises 2015 Revenue Guidance and Provides 2016 Revenue Guidance- Goleta, California, November 10, 2015 - Inogen, Inc. (NASDAQ: INGN), a medical technology c
Read more →INGNInogen Announces Participation in Stifel 2015 Healthcare Conference
GOLETA, Calif., Nov. 4, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the Company plans to participate in the Stifel 2015 Healthcare Conference in New Yor
Read more →INGNInogen to Announce Third Quarter 2015 Results on Tuesday, November 10, 2015
GOLETA, Calif., Oct. 27, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release its financial results for the third quarter of 2015 after market clo
Read more →INGNInogen Announces Second Quarter 2015 Financial Results
- Record Q2 2015 Total Revenue, Adjusted EBITDA and Net Income - - Strong Q2 2015 Revenue Growth of 44.9% Over the Same Period in 2014 - - Raises 2015 Guidance - GOLETA, Calif., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (NASDAQ:INGN), a medical technology company offering
Read more →INGNInogen Announces Second Quarter 2015 Financial Results - Record Q2 2015 Total Revenue, Adjusted EBITDA and Net Income - - Strong Q2 2015 Revenue Growth of 44.9% Over the Same Period in 2014 - - Rais
Inogen Announces Second Quarter 2015 Financial Results - Record Q2 2015 Total Revenue, Adjusted EBITDA and Net Income - - Strong Q2 2015 Revenue Growth of 44.9% Over the Same Period in 2014 - - Raises 2015 Guidance - Goleta, California, August 11, 2015 - Inogen, Inc. (NASDAQ:
Read more →INGNR. Scott Greer Joins Inogen Board of Directors Goleta, California
R. Scott Greer Joins Inogen Board of Directors Goleta, California, August 6, 2015 Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that R. Scott Greer has been appointed as an ind
Read more →INGNInogen to Announce Second Quarter 2015 Results on Tuesday, August 11, 2015
GOLETA, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release its financial results for the second quarter of 2015 after market cl
Read more →INGNInogen Vice President of Strategic Alliances, Bob Fary, Selected to Join AA Homecare Board of Directors
GOLETA, Calif., July 1, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that Bob Fary, Inogen VP of Strategic Alliances, has been selected to join the Ameri
Read more →INGNInogen Named Company of the Year at the 2015 South Coast Business & Technology Awards
GOLETA, Calif., June 12, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the home care setting, announced today that it has been honored as the Company of the Year at the South Coast Business &
Read more →INGNInogen Announces Participation in William Blair 35th Annual Growth Stock Conference
GOLETA, Calif., May 26, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the Company plans to participate in the William Blair 35th Annual Growth Stock Confe
Read more →INGNInogen Announces First Quarter 2015 Financial Results
- Record Q1 2015 Total Revenue; Growth of 42.8% Over Q1 2014 - - Reiterates 2015 Guidance - GOLETA, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the home care setting, today
Read more →INGNInogen Announces First Quarter 2015 Financial Results - Record Q1 2015 Total Revenue; Growth of 42.8% Over Q1 2014 - - Reiterates 2015 Guidance - Goleta, California
Inogen Announces First Quarter 2015 Financial Results - Record Q1 2015 Total Revenue; Growth of 42.8% Over Q1 2014 - - Reiterates 2015 Guidance - Goleta, California, May 12, 2015 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory produc
Read more →INGNInogen to Announce First Quarter 2015 Results on Tuesday, May 12, 2015
GOLETA, Calif., May 4, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release its financial results for the first quarter of 2015 after market close
Read more →INGNInogen Announces Fourth Quarter and Full Year 2014 Financial Results and Updates 2015 Outlook
- Full Year 2014 Revenue of $112.5 Million Exceeds Guidance, Up 49.2% Year over Year - - Strong Q4 2014 Revenue Growth of 47.3% Year over Year - - Raises 2015 Full Year Revenue Guidance - GOLETA, Calif., April 27, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical
Read more →INGNInogen Announces Fourth Quarter and Full Year 2014 Financial Results and Updates 2015 Outlook - Full Year 2014 Revenue of $112.5 Million Exceeds Guidance, Up 49.2% Year over Year - - Strong Q4 2014
Inogen Announces Fourth Quarter and Full Year 2014 Financial Results and Updates 2015 Outlook - Full Year 2014 Revenue of $112.5 Million Exceeds Guidance, Up 49.2% Year over Year - - Strong Q4 2014 Revenue Growth of 47.3% Year over Year - - Raises 2015 Full Year Revenue Guidan
Read more →INGNInogen to Announce Fourth Quarter and Full Year 2014 Results on Monday, April 27, 2015
GOLETA, Calif., April 24, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release its financial results for the fourth quarter and full year of 2014
Read more →INGNInogen Receives Expected NASDAQ Notice Related to Delay in Form 10-K Filing
GOLETA, Calif., April 20, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the home care setting, today announced that, as expected, it received a standard notice from NASDAQ stating that Inogen
Read more →INGNInogen Receives Expected NASDAQ Notice Related to Delay in Form 10-K Filing Goleta, California
Inogen Receives Expected NASDAQ Notice Related to Delay in Form 10-K Filing Goleta, California, April 20, 2015 Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the home care setting, today announced that, as expected,
Read more →INGNInogen Delays Filing of Form 10-K
GOLETA, Calif., April 14, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the home care setting, today announced that it is delaying the filing of its Annual Report on Form 10-K for the year end
Read more →INGNInogen Delays Filing of Form 10-K Goleta, California
Inogen Delays Filing of Form 10-K Goleta, California, April 14, 2015 Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the home care setting, today announced that it is delaying the filing of its Annual Report on Form
Read more →INGNInogen to File Form 12b-25 With Securities and Exchange Commission
GOLETA, Calif., March 31, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the home care setting, announced today that it will file a Form 12b-25 Notification of Late Filing with the U.S. Securit
Read more →INGNInogen Announces Full Operation of New Primary Manufacturing Facility
GOLETA, Calif., March 25, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the home care setting, announced today that its new manufacturing facility in Richardson, Texas is now operational suppo
Read more →INGNInogen Reaffirms 2015 Guidance, Announces Audit Committee Investigation Into Accounting Matters, Postpones Fourth Quarter and Fiscal Year 2014 Earnings Release and Conference Call
GOLETA, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that during the first quarter of 2015 certain potential accounting matters were di
Read more →INGNInogen Reaffirms 2015 Guidance, Announces Audit Committee Investigation into Accounting Matters, Postpones Fourth Quarter and Fiscal Year 2014 Earnings Release and Conference Call Goleta, California
Inogen Reaffirms 2015 Guidance, Announces Audit Committee Investigation into Accounting Matters, Postpones Fourth Quarter and Fiscal Year 2014 Earnings Release and Conference Call Goleta, California, March 11, 2015 Inogen, Inc. (Nasdaq: INGN), a medical technology company offe
Read more →INGNInogen to Announce Fourth Quarter and Full Year 2014 Results on Thursday, March 12, 2015
GOLETA, Calif., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release its financial results for the fourth quarter and full year of 2014 a
Read more →INGNInogen to Participate in Upcoming Investor Conferences
GOLETA, Calif., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that the Company will be participating in two upcoming investor conferences. Inoge
Read more →INGNInogen Donates Medical Device to Holocaust Survivor on International Holocaust Remembrance Day 2015
GOLETA, Calif., Jan. 27, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that in honor of International Holocaust Remembrance Day 2015, the Company is donat
Read more →INGNInogen Announces Reimbursement for the Inogen One G3 in Germany
GOLETA, Calif., Dec. 23, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that the Inogen One G3 portable oxygen concentrator has received coverage for insur
Read more →INGNInogen Discusses Oxygen Therapy Market and Future Growth Drivers at Investor/Analyst Day
GOLETA, Calif., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it intends to discuss the company's future growth drivers, provide a review of its
Read more →INGNInogen Discusses Oxygen Therapy Market and Future Growth Drivers at Investor/Analyst Day Reaffirms 2014 Guidance and Provides 2015 Outlook
Inogen Discusses Oxygen Therapy Market and Future Growth Drivers at Investor/Analyst Day Reaffirms 2014 Guidance and Provides 2015 Outlook GOLETA, Calif., December 15, 2014 -- Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for
Read more →INGNInogen Expands Manufacturing Capacity to Accommodate Growth
GOLETA, Calif., Dec. 5, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it has entered into a lease agreement for approximately 23,890 square feet to be use
Read more →INGNInogen Announces Investor/Analyst Day and Webcast
GOLETA, Calif., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it will host an institutional investor and analyst meeting on Monday, December 15, 2
Read more →INGNInogen Recognized as One of the Fastest Growing Companies in North America According to Deloitte's 2014 Technology Fast 500(TM)
GOLETA, Calif., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced it was included on Deloitte's Technology Fast 500 , a ranking of the 500 fastest gr
Read more →INGNInogen Releases Third Quarter 2014 Financial Results - Q3 2014 Revenues Reflect 48.6% Year over Year Growth - - Raised 2014 Revenue, Adjusted EBITDA, and Net Income Guidance - Goleta, California
Inogen Releases Third Quarter 2014 Financial Results - Q3 2014 Revenues Reflect 48.6% Year over Year Growth - - Raised 2014 Revenue, Adjusted EBITDA, and Net Income Guidance - Goleta, California, November 11, 2014 - Inogen, Inc. (NASDAQ: INGN), a medical technology company off
Read more →INGNInogen Releases Third Quarter 2014 Financial Results
- Q3 2014 Revenues Reflect 48.6% Year over Year Growth - - Raised 2014 Revenue, Adjusted EBITDA, and Net Income Guidance - GOLETA, Calif., Nov. 11, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use
Read more →INGNInogen Selects JPMorgan Chase & Co. for Primary Banking Relationship New Agreement Enables JPMorgan Chase to Provide Full Range of Financial Services Products to the Company
Inogen Selects JPMorgan Chase & Co. for Primary Banking Relationship New Agreement Enables JPMorgan Chase to Provide Full Range of Financial Services Products to the Company GOLETA, Calif., November 10, 2014 -- Inogen, Inc. (NASDAQ: INGN), a medical technology company offering
Read more →INGNInogen Selects JPMorgan Chase & Co. for Primary Banking Relationship
GOLETA, Calif., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that it has entered into a primary banking relationship with JPMorgan Chase & Co. t
Read more →INGNInogen to Participate in Stifel 2014 Healthcare Conference
GOLETA, Calif., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today the company is scheduled to participate in the Stifel 2014 Healthcare Conference in
Read more →INGNInogen Announces Closing of Secondary Public Offering
GOLETA, Calif., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN) today announced the closing of 2,415,891 shares of its common stock at $21.50 per share in a secondary offering (including 315,116 shares that were offered and sold by the selling stockholders pursuant to
Read more →INGNInogen Announces Pricing of Secondary Public Offering
GOLETA, Calif., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN) today announced the pricing of 2,100,775 shares of its common stock at $21.50 per share in a secondary offering. All of the shares will be sold by existing stockholders. In addition, the underwriters hav
Read more →INGNInogen Announces Preliminary Unaudited Third Quarter 2014 Revenue Goleta, California
Inogen Announces Preliminary Unaudited Third Quarter 2014 Revenue Goleta, California, October 27, 2014 - Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that it expects to report
Read more →INGNInogen Announces Preliminary Unaudited Third Quarter 2014 Revenue
GOLETA, Calif., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that it expects to report total revenue of at least $28 million in the third quarte
Read more →INGNInogen Announces Launch of Proposed Secondary Public Offering by Selling Stockholders
GOLETA, Calif., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN) announced today the launch of a proposed secondary public offering of 2,100,775 shares of its common stock. All of such shares will be offered and sold by certain stockholders of Inogen, and the selling
Read more →INGNInogen Announces Release to Market of the Inogen At Home(TM), an Innovative Home Oxygen Concentrator
GOLETA, Calif., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that it has released to market its innovative home oxygen concentrator called the I
Read more →INGNInogen to Announce Third Quarter 2014 Results on Tuesday, November 11, 2014
GOLETA, Calif., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release its financial results for the third quarter of 2014 after the close
Read more →INGNInogen Announces Reimbursement for the Inogen One G3 in France
GOLETA, Calif., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that the Inogen One G3 portable oxygen concentrator has received coverage for reimb
Read more →INGNInogen Releases Second Quarter 2014 Financial Results - Record Q2 2014 Revenues Reflect 51% Growth over Q2 2013 - - Raised 2014 Revenue and EBITDA Guidance - Goleta, California
Inogen Releases Second Quarter 2014 Financial Results - Record Q2 2014 Revenues Reflect 51% Growth over Q2 2013 - - Raised 2014 Revenue and EBITDA Guidance - Goleta, California, August 12, 2014 Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respi
Read more →INGNInogen Releases Second Quarter 2014 Financial Results
- Record Q2 2014 Revenues Reflect 51% Growth over Q2 2013 - - Raised 2014 Revenue and EBITDA Guidance - GOLETA, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare se
Read more →INGNInogen Strengthens Board of Directors with Addition of Heather D. Rider Goleta, California
Inogen Strengthens Board of Directors with Addition of Heather D. Rider Goleta, California, August 7, 2014 Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that Heather D. Rider h
Read more →INGNInogen Strengthens Board of Directors With Addition of Heather D. Rider
GOLETA, Calif., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that Heather D. Rider has been elected to its Board of Directors, effective immediat
Read more →INGNInogen to Release Second Quarter 2014 Financial Results and Host Conference Call on Tuesday, August 12, 2014
GOLETA, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that it will release its financial results for the second quarter of 2014 after the
Read more →INGNInogen Announces FDA Clearance of Innovative Home Oxygen Concentrator
GOLETA, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN) announced today that it has received FDA clearance for an innovative home oxygen concentrator called the Inogen At Home . The Inogen At Home is expected to be the lightest 5 liter per minute continuous
Read more →INGNInogen to Present at the William Blair 34th Annual Growth Stock Conference
GOLETA, Calif., May 27, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions, announced t
Read more →INGNInogen Founders Honored With Prestigious "Venky" Award From the University of California Santa Barbara
GOLETA, Calif., May 14, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN) along with the Technology Management Program at UC Santa Barbara's College of Engineering today announced that Ali Bauerlein, Brenton Taylor, and Byron Myers will be presented with the prestigious Venky N
Read more →INGNInogen Releases First Quarter 2014 Financial Results - Strong Q1 2014 Revenue Growth of 50% Year-over-Year - - Raised 2014 Guidance - Goleta, California
Inogen Releases First Quarter 2014 Financial Results - Strong Q1 2014 Revenue Growth of 50% Year-over-Year - - Raised 2014 Guidance - Goleta, California, May 13, 2014 Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in
Read more →INGNInogen Releases First Quarter 2014 Financial Results
- Strong Q1 2014 Revenue Growth of 50% Year-over-Year - - Raised 2014 Guidance - GOLETA, Calif., May 13, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the home care setting, today reported f
Read more →INGNInogen to Release First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 13, 2014
GOLETA, Calif., April 29, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the home care setting, announced today that it will release its financial results for the first quarter of 2014 after th
Read more →INGNInogen Added to Russell 2000(R) and 3000(R) Indexes
GOLETA, Calif., March 31, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions, announced
Read more →INGNInogen Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook - Strong Q4 2013 Revenue Growth of 43% Year over Year - - Full Year 2013 Revenue of $75.4 Million, Up 55
Inogen Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook - Strong Q4 2013 Revenue Growth of 43% Year over Year - - Full Year 2013 Revenue of $75.4 Million, Up 55% Year over Year Goleta, California, March 27, 2014 Inogen, Inc. (NASDAQ: INGN)
Read more →INGNInogen Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook
- Strong Q4 2013 Revenue Growth of 43% Year over Year - - Full Year 2013 Revenue of $75.4 Million, Up 55% Year over Year - GOLETA, Calif., March 27, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for us
Read more →INGNInogen to Release Fourth Quarter 2013 Financial Results and Host Conference Call on Thursday, March 27, 2014
GOLETA, Calif., March 12, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the home care setting, announced today that it will release its financial results for the fourth quarter of 2013 after t
Read more →INGNInogen Announces Closing of Initial Public Offering
GOLETA, Calif., Feb. 20, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN) today announced that it has closed its previously announced initial public offering of 4,411,763 shares of its common stock at a price to the public of $16.00 per share. In connection with the initial pu
Read more →INGNInogen Announces Pricing of Initial Public Offering
GOLETA, Calif., Feb. 13, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN) today announced the pricing of its initial public offering of 4,411,763 shares of its common stock at a price to the public of $16.00 per share. Inogen is offering 3,529,411 shares of common stock and ce
Read more →INGNInogen Releases Improved Inogen One G2 Oxygen Concentrator
GOLETA, Calif., Dec. 5, 2013 (GLOBE NEWSWIRE) -- Inogen announces an improved Inogen One G2 portable oxygen concentrator. This improvement on the existing product comes as part of the company's greater plan to provide oxygen therapy to increase freedom and independence for oxygen
Read more →INGNInogen Files Registration Statement With SEC for an Initial Public Offering
GOLETA, Calif., Nov. 27, 2013 (GLOBE NEWSWIRE) -- Inogen, Inc. today announced that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The number of shares to be sold and the price range fo
Read more →INGNInogen Announcing COPD Awareness Giveaway for Month of November
SANTA BARBARA, Calif., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Inogen announces the launch of a Facebook giveaway running throughout the month of November, called the "Share for COPD Awareness Giveaway". November is COPD (Chronic Obstructive Pulmonary Disease) Awareness Month nationwide
Read more →INGNInogen Salutes Decorated WWII POW Veteran and Vandenberg Staffer
SANTA BARBARA, Calif., July 17, 2012 (GLOBE NEWSWIRE) -- Puett Willcox, a decorated WWII POW survivor and Korean War Veteran, fought for his country for years overcoming unthinkable challenges, yet when he was diagnosed with COPD and required supplemental oxygen therapy he could
Read more →Competitive Position
How INGN ranks across every disease it competes inCompetitive Position is a premium feature
See how INGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial